Abstract | BACKGROUND: EXPERIMENTAL DESIGN: Immunohistochemistry for RRM1 and RRM2 was performed on a lung cancer tissue microarray (TMA) and analyzed. 326 patients from the microarray were included in this study. RESULTS: In non-small cell lung cancer (NSCLC), RRM2 expression was strongly predictive of disease-specific survival in women, non-smokers and former smokers who had quit at least 10 years prior to being diagnosed with lung cancer. Higher expression was associated with worse survival. This was not the case for men, current smokers and those who had stopped smoking for shorter periods of time. RRM1 was not predictive of survival outcomes in any subset of the patient group. CONCLUSION: RRM2, but not RRM1, is a useful predictor of survival outcome in certain subsets of NSCLC patients.
|
Authors | Vei Mah, Mohammad Alavi, Diana C Márquez-Garbán, Erin L Maresh, Sara R Kim, Steve Horvath, Lora Bagryanova, Sara Huerta-Yepez, David Chia, Richard Pietras, Lee Goodglick |
Journal | PloS one
(PLoS One)
Vol. 10
Issue 5
Pg. e0127600
( 2015)
ISSN: 1932-6203 [Electronic] United States |
PMID | 26001082
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Tumor Suppressor Proteins
- ribonucleotide reductase M2
- RRM1 protein, human
- Ribonucleoside Diphosphate Reductase
|
Topics |
- Aged
- Carcinoma, Non-Small-Cell Lung
(metabolism, mortality, pathology)
- Female
- Humans
- Lung Neoplasms
(metabolism, mortality, pathology)
- Male
- Middle Aged
- Prognosis
- Ribonucleoside Diphosphate Reductase
(metabolism)
- Sex Factors
- Smoking
- Survival Rate
- Tumor Suppressor Proteins
(metabolism)
|